Cipla signs exclusive licensing and supply agreement with Sino Biopharmaceutical (SBP Group) for HER2 bispecific ADC TQB2102, including South Africa

South Africa is expressly a licensed territory and the licensee operates a leading South African pharmaceutical business.


Coverage: The Meridian legal market record (editorial).

South Africa is expressly a licensed territory and the licensee operates a leading South African pharmaceutical business.

Record ID TX-AFR-2026-0008
Record type Commercial IP transaction
Transaction type Patent licence, Exclusive licence, In-licensing
IP rights patent, regulatory data, not specified by source
Status Signed
Qualifying date 2026-08-29
Sector Life sciences · Pharmaceuticals – oncology
African markets South Africa
Licensed territory Seven markets: India, South Africa and five other emerging markets that the release does not name.
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, independently corroborated · 2 source(s)
Last verified 2026-10-25

Parties

  • Cipla (India): licensee
  • SBP Group (China): licensor
  • CTTQ (China): licensor, manufacturer

Key terms

  • Interest: exclusive licence to develop and commercialise; Exclusivity: exclusive; Territorial scope: India, South Africa and five other emerging markets; Field of use: HER2-expressing cancers, including breast cancer

Sources

  1. Cipla and SBP Group sign exclusive licensing agreement for Rolditamig Deuderuxtecan (TQB2102), Cipla Limited, 2026-08-29
  2. Cipla licenses experimental HER2 cancer drug for India, South Africa and five other markets, CNBC TV18, 2026-08-31

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.